These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 25975423)

  • 1. Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two-way crossover trial.
    Kakuda TN; Leopold L; Nijs S; Vandevoorde A; Crauwels HM; Bertelsen KM; Stevens M; Witek J; van Delft Y; Tomaka F; Hoetelmans RM
    J Clin Pharmacol; 2014 May; 54(5):563-73. PubMed ID: 25975423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers.
    Kakuda TN; Van Solingen-Ristea R; Aharchi F; Smedt GD; Witek J; Nijs S; Vyncke V; Hoetelmans RM
    J Clin Pharmacol; 2013 Jan; 53(1):41-50. PubMed ID: 23400742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of an effect of rilpivirine on the pharmacokinetics of ethinylestradiol and norethindrone in healthy volunteers.
    Crauwels HM; van Heeswijk RP; Buelens A; Stevens M; Hoetelmans RM
    Int J Clin Pharmacol Ther; 2014 Feb; 52(2):118-28. PubMed ID: 24161160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
    Anderson MS; Kakuda TN; Hanley W; Miller J; Kost JT; Stoltz R; Wenning LA; Stone JA; Hoetelmans RM; Wagner JA; Iwamoto M
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4228-32. PubMed ID: 18838586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers.
    Schöller-Gyüre M; Kakuda TN; Sekar V; Woodfall B; De Smedt G; Lefebvre E; Peeters M; Hoetelmans RM
    Antivir Ther; 2007; 12(5):789-96. PubMed ID: 17713162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of rilpivirine on the pharmacokinetics of methadone in HIV-negative volunteers.
    Crauwels HM; van Heeswijk RP; Vandevoorde A; Buelens A; Stevens M; Hoetelmans RM
    J Clin Pharmacol; 2014 Feb; 54(2):133-40. PubMed ID: 24203510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies.
    Kakuda TN; Woodfall B; De Marez T; Peeters M; Vandermeulen K; Aharchi F; Hoetelmans RM
    J Antimicrob Chemother; 2014 Mar; 69(3):728-34. PubMed ID: 24155058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents.
    Fulco PP; McNicholl IR
    Pharmacotherapy; 2009 Mar; 29(3):281-94. PubMed ID: 19249947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic parameters of once-daily rilpivirine following administration of efavirenz in healthy subjects.
    Crauwels H; Vingerhoets J; Ryan R; Witek J; Anderson D
    Antivir Ther; 2012; 17(3):439-46. PubMed ID: 22293086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine.
    Ramanathan S; Kakuda TN; Mack R; West S; Kearney BP
    Antivir Ther; 2008; 13(8):1011-7. PubMed ID: 19195326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine.
    Crauwels H; van Heeswijk RP; Stevens M; Buelens A; Vanveggel S; Boven K; Hoetelmans R
    AIDS Rev; 2013; 15(2):87-101. PubMed ID: 23681436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.
    Schöller-Gyüre M; Kakuda TN; De Smedt G; Woodfall B; Berckmans C; Peeters M; Hoetelmans RM
    Clin Ther; 2010 Feb; 32(2):328-37. PubMed ID: 20206790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of different meal compositions and fasted state on the oral bioavailability of etravirine.
    Schöller-Gyüre M; Boffito M; Pozniak AL; Leemans R; Kakuda TN; Woodfall B; Vyncke V; Peeters M; Vandermeulen K; Hoetelmans RM
    Pharmacotherapy; 2008 Oct; 28(10):1215-22. PubMed ID: 18823217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers.
    Peeters M; Janssen K; Kakuda TN; Schöller-Gyüre M; Lachaert R; Hoetelmans RM; Woodfall B; De Smedt G
    Ann Pharmacother; 2008 Jun; 42(6):757-65. PubMed ID: 18445705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers.
    Schöller-Gyüre M; Kakuda TN; De Smedt G; Vanaken H; Bouche MP; Peeters M; Woodfall B; Hoetelmans RM
    Br J Clin Pharmacol; 2008 Oct; 66(4):508-16. PubMed ID: 18492125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.
    Kakuda TN; DeMasi R; van Delft Y; Mohammed P
    HIV Med; 2013 Aug; 14(7):421-9. PubMed ID: 23441978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and norethindrone.
    Schöller-Gyüre M; Kakuda TN; Woodfall B; Aharchi F; Peeters M; Vandermeulen K; Hoetelmans RM
    Contraception; 2009 Jul; 80(1):44-52. PubMed ID: 19501215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steady-state pharmacokinetics of etravirine and lopinavir/ritonavir melt extrusion formulation, alone and in combination, in healthy HIV-negative volunteers.
    Schöller-Gyüre M; Kakuda TN; Witek J; Akuma SH; De Smedt G; Spittaels K; Vyncke V; Hoetelmans RM
    J Clin Pharmacol; 2013 Feb; 53(2):202-10. PubMed ID: 23436265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agonism of human pregnane X receptor by rilpivirine and etravirine: comparison with first generation non-nucleoside reverse transcriptase inhibitors.
    Sharma D; Lau AJ; Sherman MA; Chang TK
    Biochem Pharmacol; 2013 Jun; 85(11):1700-11. PubMed ID: 23583259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers.
    Kakuda TN; Schöller-Gyüre M; De Smedt G; Beets G; Aharchi F; Peeters MP; Vandermeulen K; Woodfall BJ; Hoetelmans RM
    HIV Med; 2009 Mar; 10(3):173-81. PubMed ID: 19207601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.